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To investigate whether and how CRISPR-Cas9 on-target and off-target activities are affected by chromatin in eukaryotic
cells, we first identified a series of identical endogenous DNA sequences present in both open and closed chromatin regions
and then measured mutation frequencies at these sites in human cells using Cas9 complexed with matched or mismatched
sgRNAs. Unlike matched sgRNAs, mismatched sgRNAs were highly sensitive to chromatin states, suggesting that off-target
but not on-target DNA cleavage is hindered by chromatin. We next performed Digenome-seq using cell-free chromatin
DNA (now termed DIG-seq) and histone-free genomic DNA in parallel and found that only a subset of sites, cleaved in his-
tone-free DNA, were cut in chromatin DNA, suggesting that chromatin can inhibit Cas9 off-target effects in favor of its
genome-wide specificity in cells.
[Supplemental material is available for this article.]
The type II CRISPR-Cas9 system, a form of adaptive immunity in
eubacteria and archaea against foreign DNA elements, has been
successfully repurposed for genome editing in higher eukaryotic
cells (Cho et al. 2013; Cong et al. 2013; Mali et al. 2013), in which
chromosomal DNA is wrapped around histones and packaged into
chromatin. Although it has been shown that chromatin can im-
pede Cas9–DNA interactions in vitro under cell-free conditions
(Hinz et al. 2016; Horlbeck et al. 2016; Isaac et al. 2016), it remains
unknown whether and how chromatin structure can affect Cas9
on-target and off-target activities in cells. Previous studies relied
on statistical analyses of numerous single-guide RNAs (sgRNAs)
that were targeted to different sequences and sites in the genome
(Moreno-Mateos et al. 2015; Jensen et al. 2017), comparing apples
with oranges, or reporter sequences randomly integrated at geno-
mic sites (Chen et al. 2016; Daer et al. 2017; Kim et al. 2017), which
can alter chromatin states. Wu et al. (2014) and Kuscu et al. (2014)
independently showed, using chromatin immunoprecipitation
and high-throughput sequencing (ChIP-seq), that genome-wide
off-target sites bound by catalytically deficient Cas9 (dCas9) are
enriched in open chromatin regions, hinting at chromatin effects
on off-target binding in cells. We and others found, however, that
dCas9 off-target binding sites rarely overlap with Cas9 off-target
cleavage sites (Tsai et al. 2015; Kim et al. 2016), calling for further
studies.
In this study, we sought to investigate whether Cas9 nuclease
activities in human cells can be affected by differential chromatin
states, and to improve Digenome-seq, an in vitro method for pro-
filing genome-wide CRISPR off-target sites using whole-genome
sequencing (WGS) of digested genomic DNA, to account for chro-
matin states.
Results
Chromatin effects on CRISPR-Cas9 editing efficiency
We first identified 12 proto-spacer sequences found in both open
and closed chromatin regions in the humangenome,which can be
targeted by Streptococcus pyogenes Cas9 (SpCas), using ENCODE
DNase-seq data (Fig. 1A,B; The ENCODE Project Consortium.
2012) and performed DNase I digestion assays and quantitative
PCR (qPCR) to confirm chromatin states in two widely different
human cell lines, HeLa andHEK 293T. As expected, DNA sequenc-
es in open chromatin regions weremore sensitive to DNase I diges-
tion than those in closed chromatin regions (Fig. 1C;
Supplemental Fig. 1). Next, we measured frequencies of small in-
sertions and deletions (indels) induced, via error-prone nonho-
mologous end-joining (NHEJ) repair of DNA double-strand
breaks (DSBs) at these 12 pairs of Cas9 target sites that were present
in both open and closed chromatin regions (Fig. 1D; Supplemental
Table 1). Because indel frequencies were highly variable among
sgRNAs, there was no statistically significant difference between
average indel frequencies in open chromatin regions and those
in closed chromatin regions (unpaired t-test, P=0.07 or 0.21 in
HEK 293T or HeLa cells). A pair-wise comparison of each sgRNA,
however, clearly showed that Cas9 induced indels with higher fre-
quencies at sites in open chromatin regions than it did at respec-
tive sites with the same DNA sequence in closed chromatin
regions (paired t-test, P= 0.007 or 0.001 in HEK 293T or HeLa cells,
respectively) (Fig. 1D), suggesting that Cas9 cleaves target sites in
open chromatin regions more efficiently than those in closed
chromatin regions. On average, indel frequencies at open chroma-
tin sites were higher than those at closed chromatin sites by a fac-
tor of 1.6 ± 0.2 or 1.3 ±0.2 in HEK 293T or HeLa cells, respectively.
These results show that on-target sites in open chromatin regions
are marginally more accessible to Cas9 than are those in closed
chromatin regions with the same DNA sequences.
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Chromatin effects on CRISPR-Cas9 off-target activity
Next, we investigated whether and how chromatin states affect
Cas9 off-target effects using a series of mismatched sgRNAs. We
chose two on-target sequences and measured indel frequencies
at these sites in open and closed chromatin regions (Fig. 2A;
Supplemental Fig. 2). The fully matched sgRNA specific to a
proto-spacer sequence termed T1 was marginally more efficient
at the open chromatin site than at the closed chromatin site by a
factor of 1.3 (=44%/33%) in HEK 293T cells or 1.1 (=59%/48%)
in HeLa cells. Interestingly, sgRNAs with 1- or 2-nucleotide (nt)
mismatches were poorly active at the closed chromatin site but
were still quite active at the open chromatin site. Thus, indel fre-
quencies obtained with these mismatched sgRNAs at the open
chromatin site were higher than at the closed chromatin sites by
up to 530-fold in HEK 293T cells and 1100-fold in HeLa cells
(Fig. 2A).We also tested a series ofmismatched sgRNAs at the other
on-target sequences present in open and closed chromatin regions
and observed similar trends (Supplemental Fig. 2). These results
show that mismatched sgRNAs, unlike matched sgRNAs, cannot
efficiently guideCas9 to sites in closed chromatin regions, and sug-
gest that off-target effects are hindered by a closed chromatin
structure.
To confirm that Cas9 access to off-target sites is more severely
limited by chromatin states than Cas9 access to on-target sites, we
tested sgRNAs matching prevalidated off-target sites at on-target
sites in open and closed chromatin states (Fig. 2B; Supplemental
Fig. 3). Unlike on-target specific sgRNAs,
off-target specific sgRNAs with 2-nt mis-
matches efficiently discriminated open
chromatin sites from closed chromatin
sites in both HeLa and HEK 293T cells.
For example, two off-target–specific
sgRNAs designed to match prevalidated
off-target sites were quite active at the
open chromatin site with an indel fre-
quency of 3.4% or 1.3% in HeLa cells
but were inactive at the closed chromatin
site with an indel frequency of 0.05% or
0.03%, respectively, discriminating the
two sites with the same DNA sequence
by a factor of 68 or 43, respectively (Fig.
2B). In contrast, the on-target–specific
sgRNA was almost equally efficient at
the open chromatin site and the closed
chromatin site with an indel frequency
of 52% and 33%, respectively. We also
tested off-target–specific sgRNAs at other
target sites and obtained similar results in
HEK 293T cells and HeLa cells (Supple-
mental Fig. 3). We conclude that Cas9
on-target interactions are strong enough
to cause DNA cleavage and targeted mu-
tagenesis at genomic sites regardless of
thechromatin state,whereasCas9off-tar-
get interactions are in general much
weaker and, thereby, are hindered by
closed chromatin. This means that chro-
matin accessibility is in favor of ge-
nome-wide CRISPR-Cas9 specificity in
human and other higher eukaryotic cells.
DIG-seq: Digenome-seq using native chromatin DNA
Having learned that chromatin is a barrier to Cas9 off-target DNA
cleavage in cells, we sought to identify genome-wide Cas9 off-tar-
get sites in a chromatin context by using native chromatin DNA
rather than histone-free genomic DNA in a digested genome se-
quencing (Digenome-seq) analysis (Kim et al. 2015). Native chro-
matin DNA isolated from HeLa and HEK 293T cells was
incubated with the preassembled Cas9 protein (300 nM) and
sgRNA (900 nM) ribonucleoprotein (RNP) complex for ∼12 h
and subjected to WGS (Fig. 3A; Kim et al. 2015). After aligning se-
quence reads to the human reference genome (hg19), an unusual
pattern of vertical alignments, rather than staggered alignments,
of sequence reads, caused byCas9-catalyzedDNA cleavage,was ob-
served using the Integrative Genomics Viewer (IGV) at the on-tar-
get site (Fig. 3B).We then identified genome-wide in vitro cleavage
sites after assigning a DNA cleavage score, a measure of vertical
alignments of sequence reads, to each nucleotide position in the
entire human genome. With a cutoff score of 2.5 (Digenome
v. 1.0) or 0.1 (Digenome v. 2.0) (Kim et al. 2016), we identified
15 and 44 in vitro cleavage sites, respectively, using Cas9 com-
plexed to an sgRNA targeted to HBB (Fig. 3C,D; Supplemental
Table 2). We obtained the same results when sequence reads
were aligned to GRCh38 as to hg19 (Supplemental Table 3).
We also carried out DIG-seq using nuclei pellets rather than
chromatin DNA. A vast majority (77%) of DIG-seq–positive sites




Figure 1. Effects of chromatin structure onCas9 editing efficiency. (A) Schematic overviewof themeth-
od for investigating the effects of chromatin structure on Cas9 editing efficiency. (B) Representative IGV
images obtained using ENCODE DNase-seq data at two on-target sites with the same Cas9 target se-
quence present in both open and closed chromatin regions. (C) Relative fractions of intact genomic
DNA not cleaved by DNase I measured using real-time quantitative PCR at the Cas9 target site in HeLa
cells. The range 0–32U denotes the concentration of DNase I. Error bars, SEM from at least three indepen-
dent experiments. (D) SpCas9-induced mutation frequencies at 12 pairs of endogenous target sites with
the same DNA sequence present in both open and closed chromatin regions in HEK 293T or HeLa cells.
Indel frequencies weremeasured using targeted deep sequencing. Pairs of Cas9 target sites are represent-
ed with dots with different colors. Mean indel frequencies ± SEM are shown (n=12 target sites).
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pellets. Thus, we observed a strong correlation (Pearson’s correla-
tion coefficient R2 =0.93) between DNA cleavage scores obtained
usingnuclei pellets and thoseobtainedusingchromatinDNA(Sup-
plemental Fig. 4).
We next performed DIG-seq using chromatin DNA isolated
from K562 cells, T cells, and H9 human embryonic stem cells.
Most of the in vitro cleavage sites, especially those with high
DNA cleavage scores, were commonly identified, regardless of
cell type (Supplemental Table 2), suggesting that chromatin ef-
fects on Cas9 off-target DNA cleavage, at least with the




Figure 2. Effects of chromatin structure on Cas9 activity at off-target sites. (A) Mismatched sgRNAs that differed from the Cas9 target sequence by 1 or 2
nt were targeted to sites in both open (blue) and closed (red) chromatin regions in HEK 293T and HeLa cells. Indel frequencies were measured using tar-
geted deep sequencing. Error bars, SEM (n=3). (B) Indel frequencies at the on-target sites in open and closed chromatin states using on-/off-target specific
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We compared in vitro cleavage sites obtained using native
chromatin DNA with those obtained using histone-free DNA. Use
of histone-free DNA in a Digenome-seq analysis yielded many ad-
ditional in vitro cleavage sites. Thus, with Digenome v. 1.0, 15 or
48 sites were cleaved using native chromatin DNA and histone-
free DNA, respectively. Fourteen out of 15 (=93%) sites captured
by DIG-seq were also identified by Digenome-seq using histone-
free DNA.With Digenome v. 2.0, 44 or 97 sites were cleaved using
native chromatin DNA and histone-free DNA, respectively. Forty-
three out of 44 (=98%) sites captured using chromatin DNA were
also identified using histone-free DNA. We found, however, that
DNA cleavage scores at these in vitro cleavage sites obtained using
native chromatinwere poorly correlatedwith those obtainedusing
histone-free genomic DNA (R2=0.22
[Digenome v. 1.0] or 0.19 [Digenome
2.0]) (Fig. 3E; Supplemental Fig. 5A).
Validating off-target effects
at Digenome-identified sites
Wenext investigated the relationship be-
tween DNA cleavage scores and indel fre-
quencies at off-target sites validated by
next-generation sequencing (NGS). We
measured indel frequencies at all of the
49 in vitro cleavage sites revealed with
Digenome v. 1.0 in HeLa cells (Supple-
mental Fig. 5B; Supplemental Table 4)
and identified four bona fide off-target
sites at which indel frequencies were
greater than background sequencing er-
ror rates. No indels were detectably in-
duced at 34 in vitro cleavage sites
detected by Digenome-seq using his-
tone-free DNA butmissed by DIG-seq us-
ing chromatin DNA (Supplemental Fig.
5B; Supplemental Table 5). There was es-
sentially no correlation between DNA
cleavage scores obtained using his-
tone-free DNA and indel frequencies at
these validated off-target sites (R2=
0.07) (Supplemental Fig. 5C). Interest-
ingly, however, we observed a strong cor-
relation between DNA cleavage scores
obtained using chromatin DNA and
indel frequencies (R2 = 0.72) (Fig. 3F).
We next performed DIG-seq with
seven additional sgRNAs individually
(Supplemental Table 4) and compared
the results with those obtained using his-
tone-free DNA. As expected, fewer sites
were cleaved in chromatin DNA than in
histone-free DNA by Cas9. Thus, a total
of eight sgRNAs in complex with Cas9
cleaved chromatin DNA and histone-
free DNA at 18±6 and 85± 19 sites, on
average, respectively. Most sites (66%–
100%, on average 91%) cleaved in chro-
matin DNA were also cleaved in his-
tone-free DNA (Fig. 3C; Supplemental
Fig. 6; Supplemental Table 6).
We measured indel frequencies at
these in vitro cleavage sites identified by DIG-seq using chromatin
DNA to validate Cas9 off-target effects in cells. Forty-nine out of
138 sites tested in this study were validated to be bona fide off-tar-
get sites. Indel frequencies at these validated off-target sites ranged
from 0.07% (FANCF-5 in Supplemental Table 4) to 39% (EMX1-4
in Supplemental Table 4). Validation rates of DIG-seq were higher
than those of Digenome-seq. Thus, among 15 DIG-seq–positive
sites identified using theHBB sgRNAviaDigenome v. 1.0, four sites
were validated using deep sequencing, resulting in a validation rate
of 27%, whereas among 48 Digenome-seq–positive sites via
Digenome v. 1.0, the same four sites were validated, resulting in
a validation rate of 8.3%. Likewise, the DIG-seq validation rate







Figure 3. DIG-seq using native chromatin DNA. (A) Overview of DIG-seq to identify genome-wide
Cas9 in vitro cleavage sites using native chromatin DNA. (B) A representative IGV image showing a stag-
gered alignment (top) and a straight alignment (bottom) of whole-genome sequence reads at the on-tar-
get site. (C) A Venn diagram showing the number of in vitro cleavage sites identified by Digenome-seq
using histone-free DNA or by DIG-seq using chromatin DNA with the HBB-targeted CRISPR-Cas9.
(D) Sequence logos obtained via WebLogo using in vitro cleavage sites captured by Digenome-seq or
DIG-seq. (E) Scatterplot of DNA cleavage scores at sites captured by Digenome-seq versus DIG-seq.
(F) Scatterplot of indel frequencies versus DNA cleavage scores at sites captured by DIG-seq using
HeLa chromatin DNA. (G) Pearson’s correlation coefficients (R-square values) obtained with indel fre-
quencies versus DNA cleavage scores at off-target sites identified by Digenome-seq using chromatin
or histone-free DNA. Error bars, SEM (n=5). The P-value was calculated by Student’s t-test.
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seq validation rate was 23% (=3/13). The sites detected exclusively
by DIG-seq (one site for the HBB sgRNA, 10 sites for the FANCF
sgRNA, and one site for the EMX1 sgRNA) were not validated
by targeted deep sequencing. It is possible that these sites were
mutated at frequencies below detection limits of targeted ampli-
con sequencing. This means that DIG-seq using chromatin DNA
is as sensitive and comprehensive as Digenome-seq using his-
tone-free DNA. Again, we observed a strong correlation between
DNA cleavage scores obtained using chromatin DNA and indel fre-
quencies determined using NGS at validated off-target sites (Fig.
3G; Supplemental Fig. 7). In contrast, DNA cleavage scores ob-
tained using histone-free DNA were poorly correlated with indel
frequencies. This result suggests that a DNA cleavage score ob-
tained using chromatin DNA rather than histone-free DNA could
serve as an estimate of genome editing efficiency in cells. It is often
impractical to validate off-target effects in cells usingNGS at all the
candidate sites cleaved in vitro because the number of such sites
can reach hundreds to thousands, depending on the sgRNAs
(Tsai et al. 2015; Kim et al. 2016). In these cases, one could choose
the sites with the top cleavage scores obtained using chromatin
DNA for validating off-target effects via NGS.
We also found DIG-seq–positive sites were more likely to fall
within open-chromatin regions than were Digenome-seq–positive
sites. Among 139 DIG-seq–positive sites identified using the other
seven sgRNAs, seven sites (=5.0%) were found in DNase I hyper-
sensitive regions,whereas among358Digenome-seq–positive sites
identified using the same seven sgRNAs, just four sites (=1.1%)
were found in DNase I hypersensitive regions (Supplemental
Tables 4, 7).
Digenome-seq and other methods
We also compared our new method with CIRCLE-seq (Tsai et al.
2017) and SITE-seq (Cameron et al. 2017), recently reported cell-
free methods for characterizing CRISPR off-target effects in vitro.
Among the eight sgRNAs we analyzed in this study, two sgRNAs,
namely those targeted to the VEGFA site and the FANCF site,
had also been tested by Tsai et al. (2017) and Cameron et al.
(2017), although they used genomic DNA isolated from different
cell lines. We found that none of these methods, including
Digenome-seq with histone-free DNA, were comprehensive (Fig.
4). SITE-seq produced the most outputs: 996 sites and 162 sites
were identified using the VEGFA-specific sgRNA and the FANCF-
specific sgRNA, respectively (Cameron et al. 2017). DIG-seq yield-
ed by far the fewest sites, 31 and 36, respectively, even with the
more comprehensive Digenome v. 2.0 program (Kim et al. 2016).
Among these sites, 29 out of 31 (94%) and 21 out of 36 (58%), re-
spectively, were also captured by both CIRCLE-seq and SITE-seq.
We validated off-target effects in cells at the 29 sites commonly
identified via the four different methods using the VEGFA-specific
sgRNA and found that 16 sites were bona fide off-targets, resulting
in a validation rate of 62% (=18/29). Because CIRCLE-seq and
SITE-seq, in general, yield more outputs than Digenome-seq using
histone-free DNA, validation rates with sites identified using these
cell-free methods are much lower, ranging from 10% (SITE-seq)
(Cameron et al. 2017) to 29% (CIRCLE-seq) (Tsai et al. 2017).
Discussion
Genome-wideCRISPRoff-target sites canbe identified byanumber
of unbiased cell-free or cell-based methods (Koo et al. 2015; Tsai
and Joung 2016). Each of these methods has its own pros and
cons. DIG-seq is unique in that it is an in vitro (cell-free) method
but nevertheless accounts for chromatin structure in eukaryotic
cells.ChromatinDNAcanbeeasilyprepared fromanycells of inter-
est by lysis and centrifugation and used for digestion with Cas9 or
other nucleases in vitro. In contrast, GUIDE-seq, awidely used cell-
based method, requires transfection of double-stranded oligonu-
cleotides into cells (Tsai et al. 2015). GUIDE-seq cannot be used
incertaincells that are refractory to transfection. Furthermore, dou-
ble-stranded oligonucleotides are cytotoxic to many primary cells.
DIG-seqdoesnot relyon transfectionand is thereby free fromthese
limitations. In addition, DIG-seq retains all of the advantages of
Digenome-seq over other cell-free or cell-basedmethods,which in-
clude no adapter ligation or DNA amplification prior to deep se-
quencing, no need for homology searches (Digenome v. 1.0) to
identify potential off-target sites, and no DNA resection in vitro
by cellular repair enzymes, making it possible to pinpoint DSB
ends precisely.
Cell-freemethodsprovidea listofpotential off-target sites that
are cleaved invitro.Nomutations are, however, detectably induced
at most of these sites in cells (Kim et al. 2015, 2016). According to
our Digenome analysis using chromatin DNA, most of these in vi-
tro cleavage sites are not cleaved in a chromatin context. NGS
validation is an essential step for confirming and measuring ge-
nome-wide off-target effects but is time-consuming, expensive,
and labor-intensive. In this regard, DIG-seq is advantageous over
Figure 4. Comparison of DIG-seq with other in vitro methods. Venn diagrams showing the number of in vitro cleavage sites identified by DIG-seq,
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other cell-freemethods because it provides a list ofmuch fewer sites
that are cleaved in a chromatin context than do other methods.
We note that there were several off-target candidate sites (e.g.,
HBB-3, HBB-5, HBB-6, etc., in Supplemental Table 4) captured by
DIG-seq with relatively high DNA cleavage scores that were not
validated by targeted deep sequencing. It is possible that these sites
were mutated in cells at frequencies blow detection limits of deep
sequencing, which range from 0.001%–1% (0.1% on average).
Another possibility is that these sites were cleaved in cells efficient-
ly but repaired seamlessly either via error-free NHEJ or HDR.
In conclusion, we found that CRISPR-Cas9 access to on-target
and off-target sites is limited by chromatin structure in cells and
that Cas9 interactions with sgRNA-mismatched sites are much
more sensitive to the chromatin state than are those withmatched
sites, suggesting that chromatin enhances genome-wide CRISPR
specificity in human and other eukaryotic cells. These results
prompted us to develop DIG-seq using chromatin DNA rather
than histone-free DNA in vitro for characterizing genome-wide
CRISPR off-target effects in a chromatin context. We expect that
DIG-seqwill bewidely used for identifying CRISPR-Cas9 and other
nuclease off-target sites sensitively and comprehensively to facili-
tate therapeutic genome editing.
Methods
Cas9 protein purification and in vitro sgRNA transcription
Recombinant Cas9 protein was purchased from ToolGen. sgRNAs
were synthesized by in vitro transcription using T7 RNA polymer-
ase as described previously (Kim et al. 2016). Briefly, sgRNA tem-
plates were incubated with T7 RNA polymerase in reaction buffer
(40 mM Tris-HCl, 6 mM MgCl2, 10 mM DTT, 10 mM NaCl,
2 mM spermidine, NTPs, and RNase inhibitor, at pH 7.9) for 8 h
at 37°C and mixed with DNase I to remove sgRNA template
DNA. Transcribed sgRNAs were purified using PCR purification
kits (Macrogen).
Cell culture and transfection conditions
HEK 293T cells (ATCC CRL-11268) and HeLa cells (ATCC CCL-2)
were cultured in DMEM media supplemented with 10% FBS and
1% penicillin/streptomycin (Welgene). HEK 293T cells (1.5 × 105)
or HeLa cells (8 × 104) were seeded on 24-well plates and co-
transfected with the Cas9 expression plasmid (500 ng) and the
sgRNA-encoding plasmid (500 ng) using Lipofectamine 2000
(Life Technologies). K562 cells (ATCC) were maintained in RPMI
medium supplemented with 10% FBS and 1% penicillin/strepto-
mycin (Welgene).
DNase I digestion assays and qPCR
We washed 2×107 cells twice with PBS and incubated them with
DNase I (4–32 units) in a reaction volume of 120 µL (10 mM
NaCl, 10 mM Tris-HCl, 3 mM MgCl2, and 0.1% NP-40, at pH
7.4) for 30 min at 37°C. One hundred sixty microliters of 50 mM
EDTA was added to stop the reaction. DNase I–digested DNA was
purified with a DNeasy tissue kit (Qiagen). Digested DNA was
mixed with KAPA SYBR FAST qPCR master mix (Kapa Biosystems)
and analyzed by real-time qPCR. The fraction of intact genomic
DNA was measured using the comparative CT method; 2
−ΔΔCT =
[(CT site of interest of DNase I untreated or treated sample−CT in-
ternal control of DNase I untreated or treated sample)− (CT site of
interest of DNase I untreated sample−CT internal control of
DNase I untreated sample)] (Schmittgen and Livak 2008).
Identification of identical Cas9 target sequences that are present
in both open and closed chromatin regions
To find Cas9 target sequences present in both open and closed
chromatin regions, we first identified Cas9 target sequences that
occur twice in the genome. By using ENCODE DNase-seq data ob-
tained fromHEK293T andHeLa cells, wemanually identified Cas9
target sequences with a high sequencing depth at one site and a
low depth at the other site, corresponding to an open chromatin
site and a closed chromatin site, respectively.
In vitro cleavage of native chromatin DNA
We lysed 5×105 cells with lysis buffer (1× PBS, 0.4% NP-40, and 3
mMMgCl2) and centrifuged them at 500g for 5min. After removal
of supernatant, nuclei pellets were mixed with Nuc-lysis solution
(10mMEDTA, 0.5mMEGTA, 0.1% Triton X-100) and centrifuged
at 500g for 5min. Nuclei pellets or native chromatin were incubat-
ed with 300 nM of Cas9 and 900 nM of sgRNA for 8 h in reaction
buffer (100mMNaCl, 50mMTris-HCl, 10mMMgCl2, and 100µg/
mL BSA, at pH 7.9). Digested genomicDNAwas treatedwith RNase
A (50 µg/mL) to degrade sgRNAs and was purified again with a
DNeasy tissue kit (Qiagen).
WGS and Digenome sequencing
One microgram of genomic DNA was sonicated to 400- to 500-bp
fragments using the Covaris system (Life Technologies), and over-
hangs were removed using the end repair mix. Fragmented DNA
was ligated with adapters to produce libraries, which were then
subjected to WGS using an Illumina HiSeq X Ten Sequencer at
Macrogen. WGS was performed at a sequencing depth of 30–40×
with the following mapping program and parameters: Isaac align-
er, ver. 01.14.03.12; human genome reference, hg19 or GRCh38;
base quality cutoff, 15; keep duplicate reads, yes; variable read
length support, yes; realign gaps, no; and adapter clipping, yes
(adapter: AGATCGGAAGAGC∗,∗GCTCTTCCGATCT). DNA cleav-
age scores at the DNA target sites were calculated using the
Digenome 1.0 and Digenome 2.0 programs (https://github.com/
chizksh/digenome-toolkit2). As described in our previous paper
(Kim et al. 2017), the cutoff value was determined experimentally.
Briefly, we counted the number of sites whoseDNA cleavage scores
were over a cutoff value that ranged from 0.0001 to 10 and the
number of PAM-containing sites with 10 or fewer mismatches
among the sites with scores over the cutoff value (Supplemental
Fig. 8). We chose a cutoff value of 0.1 because WGS data obtained
using intact genomic DNA, which served as a negative control, did
not yield any false-positive sites with this cutoff score (Digenome
v. 2.0).
Targeted deep sequencing
Genomic DNA segments spanning the on-target and potential off-
target sites were amplified by Phusion polymerase (New England
Biolabs), and PCR amplicons were subjected to paired-end se-
quencing using Illumina MiSeq. The resulting sequencing files
were subjected to Cas-Analyzer (http://www.rgenome.net/cas-
analyzer/) to calculate indel frequencies (Park et al. 2017).
Data access
The next-generation sequencing data from this study have been
submitted to the NCBI Sequence Read Archive (SRA; https://www
.ncbi.nlm.nih.gov/sra) under accession numbers SRP067307 and
SRP158339.
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